BROOMFIELD, Colo., May 8 /PRNewswire/ -- Accera Inc. announced today that the company will participate in three upcoming healthcare investor conferences.
Dr. Steve Orndorff, President and CEO, will present at the Rodman & Renshaw 4th Annual Global Healthcare Conference on May 16 at 11:30 a.m. at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. Later that week he will also present at the Neurotech Industry Investing & Business Conference on May 18 at 11:15 a.m. at the Westin San Francisco Airport Hotel in Millbrae, California, and then on May 24 at the C21 BioVentures 9th Annual Private Lifescience Company Conference at 10:00 a.m. at the Monterey Plaza Hotel in Monterey, California.
Dr. Orndorff will provide an overview of Accera and its technology platform as well as a summary of the positive data from a Phase IIb study of its lead candidate AC-1202 in Alzheimer's disease, which were presented last week at the American Academy of Neurology 59th Annual Meeting in Boston. Accera will present the results of a six-month open-label extension of this trial at the Alzheimer's Association International Conference on Prevention of Dementia on June 11th in Washington, D.C.
About Accera, Inc.
Based in Broomfield, CO, Accera, Inc. is a privately held biotechnology company focused on developing novel drugs for neurodegenerative diseases. The company's lead candidate, AC-1202, is a first-in-class molecule that recently completed successful Phase II clinical trials for Alzheimer's disease and Age- Associated Memory Impairment. A key element of Accera's strategy is to develop AC-1202 and other proprietary small molecule compounds in its pipeline with corporate partners for a range of memory and cognition disorders associated with neurological conditions and aging. http://www.accerapharma.com
About AC-1202
Brain imaging techniques performed on AD patients reveal a dramatically decreased uptake of glucose, the brain's preferred source of energy. AC-1202 is an orally available, liquid compound that is efficiently converted into ketone bodies, an alternative energy source that is exclusively utilized by neurons in those areas of the brain most affected by this metabolic dysfunction. By preserving glucose-deprived neurons, AC-1202 has neuroprotective and disease modifying potential in AD and a number other neurodegenerative diseases characterized by neuronal hypometabolism. This first-in-class compound is also being evaluated in Age-Associated Memory Impairment, Parkinson's disease and selected orphan drug indications.
For information contact: Meghan Feeks Richard Lewis Communications, Inc. 212-827-0020 mfeeks@rlcinc.com
Accera, Inc.CONTACT: Meghan Feeks of Richard Lewis Communications, Inc.,+1-212-827-0020, mfeeks@rlcinc.com
Web site: http://www.accerapharma.com/
